{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:51:00Z","timestamp":1794282660836,"version":"4.9.0"},"reference-count":52,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>(1) Background: Individuals carrying a pathogenic transthyretin gene variant (TTRv) are at high risk for developing hereditary transthyretin (ATTRv) amyloidosis and are routinely screened for the development of cardiomyopathy (ATTRv-CM). This study aims to evaluate whether the cardiac biomarkers N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) can be used to rule out ATTRv-CM. (2) Methods: In this retrospective case-control study, data from 46 ATTRv-CM patients and 101 TTRv carriers and ATTRv amyloidosis patients without cardiomyopathy were included. Binary logistic regression models were used to assess the ability of NT-proBNP and hs-cTnT to predict the diagnosis of ATTRv-CM. An optimal cutoff for the relevant biomarker(s) was determined based on a sensitivity of \u226599% and the highest possible percentage of additional tests avoided (%ATA) in the index dataset. (3) Results: Hs-cTnT demonstrated the highest predictive capabilities for ATTRv-CM. The addition of NT-proBNP did not improve the predictive model. A hs-cTnT cutoff of &lt;6 ng\/L resulted in a 97% sensitivity and a negative predictive value of 95% with a %ATA of 30% in the validation dataset. (4) Conclusion: In conclusion, hs-cTnT is a useful biomarker for excluding cardiac involvement in TTRv carriers and ATTRv amyloidosis patients and it has the potential to prevent unnecessary diagnostic procedures.<\/jats:p>","DOI":"10.3390\/jcm13030810","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T12:06:58Z","timestamp":1706616418000},"page":"810","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["High-Sensitivity Cardiac Troponin T to Exclude Cardiac Involvement in TTR Variant Carriers and ATTRv Amyloidosis Patients"],"prefix":"10.3390","volume":"13","author":[{"given":"Hendrea S. A.","family":"Tingen","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1056-0482","authenticated-orcid":false,"given":"Milou","family":"Berends","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8414-958X","authenticated-orcid":false,"given":"Alwin","family":"Tubben","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0375-4460","authenticated-orcid":false,"given":"Johan","family":"Bijzet","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewout J.","family":"Houwerzijl","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friso L. H.","family":"Muntinghe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart-Jan","family":"Kroesen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"van der Zwaag","sequence":"additional","affiliation":[{"name":"Department of Genetics, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5565-1164","authenticated-orcid":false,"given":"Riemer H. J. A.","family":"Slart","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"},{"name":"Biomedical Photonic Imaging Group, Faculty of Science and Technology, University of Twente, Drienerlolaan 5, 7522 NB Enschede, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1827-0482","authenticated-orcid":false,"given":"Bouke P. C.","family":"Hazenberg","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Clinical Immunology, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3974-6830","authenticated-orcid":false,"given":"Hans L. A.","family":"Nienhuis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0969-2126(97)00215-3","article-title":"Amyloid fibril formation and protein misassembly: A structural quest for insights into amyloid and prion diseases","volume":"5","author":"Kelly","year":"1997","journal-title":"Structure"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS\u2014The Transthyretin Amyloidosis Outcomes Survey: Initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.amjcard.2022.09.011","article-title":"Counseling Family Members and Monitoring for Evidence of Disease in Asymptomatic Carriers of Amyloid Transthyretin Cardiac Amyloidosis","volume":"185","author":"Barker","year":"2022","journal-title":"Am. J. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","article-title":"Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis","volume":"29","author":"Ando","year":"2022","journal-title":"Amyloid"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e008193","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ. Heart Fail."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Russo, M., Gentile, L., Di Stefano, V., Di Bella, G., Minutoli, F., Toscano, A., Brighina, F., Vita, G., and Mazzeo, A. (2021). Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area. Brain Sci., 11.","DOI":"10.3390\/brainsci11050545"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.amjcard.2017.09.029","article-title":"Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide","volume":"121","author":"Klaassen","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"116813","DOI":"10.1016\/j.jns.2020.116813","article-title":"Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies","volume":"414","author":"Ueda","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","article-title":"ATTR Amyloidosis: Current and Emerging Management Strategies","volume":"3","author":"Griffin","year":"2021","journal-title":"JACC CardioOncology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/mus.25210","article-title":"Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy","volume":"54","author":"Schmidt","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","article-title":"European Network for TTR-FAP (ATTReuNET) Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis","volume":"29","author":"Obici","year":"2016","journal-title":"Curr. Opin. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s13023-020-01633-z","article-title":"Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: A multicenter Italian consensus","volume":"15","author":"Grandis","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s12350-019-01950-2","article-title":"Serial scanning with 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid (99mTc-DPD) for early detection of cardiac amyloid deposition and prediction of clinical worsening in subjects carrying a transthyretin gene mutation","volume":"28","author":"Minutoli","year":"2021","journal-title":"J. Nucl. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1007\/s12350-019-01970-y","article-title":"What is the optimal cardiac screening for asymptomatic transthyretin gene mutation carriers?","volume":"28","author":"Cho","year":"2021","journal-title":"J. Nucl. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jacc.2016.04.035","article-title":"Cardiac Amyloid Load","volume":"68","author":"Kristen","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Rapezzi","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Di Lisi, D., Brighina, F., Manno, G., Comparato, F., Di Stefano, V., Macaione, F., Damerino, G., Di Caccamo, L., Cannizzo, N., and Ortello, A. (2023). Hereditary Transthyretin Amyloidosis: How to Differentiate Carriers and Patients Using Speckle-Tracking Echocardiography. Diagnostics, 13.","DOI":"10.3390\/diagnostics13243634"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jcmg.2016.06.003","article-title":"Can 99mTc-Pyrophosphate Aid in Early Detection of Cardiac Involvement in Asymptomatic Variant TTR Amyloidosis?","volume":"10","author":"Haq","year":"2017","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jcmg.2011.03.016","article-title":"Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis","volume":"4","author":"Rapezzi","year":"2011","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/13506129.2013.871250","article-title":"Bone scintigraphy with (99 m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis","volume":"21","author":"Glaudemans","year":"2014","journal-title":"Amyloid"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1536\/ihj.21-336","article-title":"Early Detection of Cardiac Amyloidosis in Transthyretin Mutation Carriers","volume":"63","author":"Nagano","year":"2022","journal-title":"Int. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1007\/s12350-023-03297-1","article-title":"Diagnostic accuracy of bone scintigraphy imaging for transthyretin cardiac amyloidosis: Systematic review and meta-analysis","volume":"30","author":"Ahluwalia","year":"2023","journal-title":"J. Nucl. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jcmg.2022.07.008","article-title":"Multi-Imaging Characterization of Cardiac Phenotype in Different Types of Amyloidosis","volume":"16","author":"Ioannou","year":"2023","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/joim.12585","article-title":"One mutation, two distinct disease variants: Unravelling the impact of transthyretin amyloid fibril composition","volume":"281","author":"Suhr","year":"2017","journal-title":"J. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/03009734.2015.1122687","article-title":"99mTc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis","volume":"121","author":"Pilebro","year":"2016","journal-title":"Upsala J. Med. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jcmg.2019.10.015","article-title":"Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis","volume":"13","author":"Musumeci","year":"2020","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","article-title":"Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations","volume":"26","author":"Damy","year":"2019","journal-title":"Amyloid"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/ejhf.3036","article-title":"Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC","volume":"25","author":"Docherty","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ejhf.2769","article-title":"N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis","volume":"25","author":"Vergaro","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/13506129.2013.825240","article-title":"Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis","volume":"20","author":"Damy","year":"2013","journal-title":"Amyloid"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2796.2007.01888.x","article-title":"Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis?","volume":"263","author":"Suhr","year":"2008","journal-title":"J. Intern. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/13506120903421538","article-title":"Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: New evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis","volume":"16","author":"Lehrke","year":"2009","journal-title":"Amyloid"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1373\/clinchem.2009.132654","article-title":"Analytical validation of a high-sensitivity cardiac troponin T assay","volume":"56","author":"Giannitsis","year":"2010","journal-title":"Clin. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ehf2.12203","article-title":"Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis","volume":"5","author":"Takashio","year":"2018","journal-title":"ESC Heart Fail."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99m Tc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0735-1097(02)02059-4","article-title":"Plasma brain natriuretic peptide concentration: Impact of age and gender","volume":"40","author":"Redfield","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1309\/AJCP60HTPGIGFCNK","article-title":"The Effect of Renal Dysfunction on BNP, NT-proBNP, and Their Ratio","volume":"133","author":"Srisawasdi","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.jacc.2013.12.032","article-title":"Age- and Sex-Dependent Upper Reference Limits for the High-Sensitivity Cardiac Troponin T Assay","volume":"63","author":"Gore","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1373\/clinchem.2016.254748","article-title":"Interpreting Cardiac Biomarkers in the Setting of Chronic Kidney Disease","volume":"63","author":"deFilippi","year":"2017","journal-title":"Clin. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00259-016-3415-4","article-title":"The EANM practice guidelines for bone scintigraphy","volume":"43","author":"Strobel","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1253\/jcj.65.395","article-title":"Effect of Angiotensin-Converting Enzyme Inhibition on Sympathetic Tone in Patients with Mild to Moderate Heart Failure","volume":"65","author":"Inoko","year":"2001","journal-title":"Jpn. Circ. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/07853890701232057","article-title":"The effects of medications on circulating levels of cardiac natriuretic peptides","volume":"39","author":"Troughton","year":"2007","journal-title":"Ann. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/01.CIR.0000036747.68104.AC","article-title":"Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The Valsartan Heart Failure Trial (Val-HeFT)","volume":"106","author":"Latini","year":"2002","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(01)01116-0","article-title":"Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure","volume":"37","author":"Tsutamoto","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0002-9343(02)01121-X","article-title":"B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure","volume":"112","author":"Yoshimura","year":"2002","journal-title":"Am. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/clc.22281","article-title":"Improved Rate Control Reduces Cardiac Troponin T Levels in Permanent Atrial Fibrillation","volume":"37","author":"Ulimoen","year":"2014","journal-title":"Clin. Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/3\/810\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:52:01Z","timestamp":1760104321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/3\/810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["jcm13030810"],"URL":"https:\/\/doi.org\/10.3390\/jcm13030810","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]}}}